JAPAN’S AVIGAN STUDY FAILS TO PROVE EFFICACY VS COVID-19

One of the clinical studies for the antiviral drug Avigan developed by a Japanese company failed to demonstrate a significant difference between coronavirus patients receiving the treatment and the control group.

Fujita Health University, which conducted the test, made the admission on Friday, July 10, 2020, Kyodo news agency reported.

Avigan, also known as favipiravir and developed by a subsidiary of Fujifilm Holdings Corp., has been seen as a possible treatment for COVID-19, the respiratory disease caused by the novel coronavirus.

The drug is one of nearly two dozen drugs being tested to reduce the suffering of COVID-19 patients and at least 19 vaccines are also trial.